THE SCIENCE
Improving care outcomes for at-risk patients — with evidence, not just claims.
Individuals bedridden for a week or longer are at real risk of pressure injury. In preclinical head-to-head testing, DuraDerma has been demonstrated to reduct the risk of pressure ulcers compared to the standard of care and other competing products.
THE CLINICAL PROBLEM
Pressure ulcers: a persistent, unaddressed burden
Pressure ulcers, also known as bedsores or decubitus ulcers, form at points of prolonged pressure — progressing from non-blanchable skin to exposed muscle and bone. Addressing the injury at Stages 1–2 avoids the steep cost of progression.
A NEVER EVENT
Why hospitals cannot ignore pressure ulcers
Stage III and IV hospital-acquired pressure ulcers are classified as “never events.” The economics fall entirely on the hospital — creating a strong, structural pull for a product that prevents them.
8.4% in inpatient hospitals; 11% in nursing-home residents; 25% of NICU patients; 420M global hospitalizations per year; 12.8% incidence globally in hospitalized adults; 2.5M pressure ulcers in the US annually.
MECHANISM OF ACTION
Reinforce the skin before deep-tissue injury occurs
DuraDerma works upstream of the wound — strengthening intact skin so it withstands the mechanical stress that initiates pressure injury.
PRECLINICAL EVIDENCE
Head-to-head against leading products
In preclinical evaluation versus leading competitor products, including Cavilon® / 3M, DuraDerma outperformed on the three measures that matter most: Collagen preservation, pressure ulcer progression, fewer inflammatory cells. Illustrative of reported findings; detailed datasets available under CDA.
WHERE DURADERMA IS USED
Primary markets
